Read by QxMD icon Read

Negative schizophrenia

Laxman Cetty, Shazana Shahwan, Pratika Satghare, Fiona Devi, Boon Yiang Chua, Swapna Verma, Helen Lee, Siow Ann Chong, Mythily Subramaniam
BACKGROUND: Hazardous alcohol use has often been found to be more prevalent amongst psychiatric outpatients than the general population. Additionally, it has also been associated with poorer outcomes. The study aimed to investigate (1) the prevalence and (2) socio-demographic and clinical correlates of hazardous alcohol use, as well as (3) the relationship between hazardous alcohol use and quality of life in an outpatient sample with First Episode Psychosis (FEP) in Singapore. METHODS: Baseline data (N = 280) was extracted from a longitudinal study investigating smoking and alcohol use amongst outpatients with FEP in a psychiatric hospital...
March 15, 2019: BMC Psychiatry
Philipp Stämpfli, Stefan Sommer, Andrei Manoliu, Achim Burrer, André Schmidt, Marcus Herdener, Erich Seifritz, Stefan Kaiser, Matthias Kirschner
Altered cerebral connectivity is one of the core pathophysiological mechanism underlying the development and progression of information-processing deficits in schizophrenia. To date, most diffusion tensor imaging (DTI) studies used fractional anisotropy (FA) to investigate disrupted white matter connections. However, a quantitative interpretation of FA changes is often impeded by the inherent limitations of the underlying tensor model. A more fine-grained measure of white matter alterations could be achieved by measuring fiber density (FD) - a novel non-tensor-derived diffusion marker...
March 15, 2019: Scientific Reports
Thomas W Scheewe, Frederike Jörg, Tim Takken, Jeroen Deenik, Davy Vancampfort, Frank J G Backx, Wiepke Cahn
Introduction: The aim of this study was to objectively assess time spent in physical activity (PA) and sedentary behavior (SB) in patients with schizophrenia compared to healthy controls matched for age, gender and socioeconomic status. Associations between both PA and cardiorespiratory fitness (CRF) and mental and physical health parameters in patients with schizophrenia were examined. Materials and Methods: Moderate and vigorous PA (MVPA), moderate PA, vigorous PA, total and active energy expenditure (TEE and AEE), number of steps, lying down and sleeping time was assessed with SenseWear Pro-2 body monitoring system for three 24-h bouts in patients with schizophrenia ( n = 63) and matched healthy controls ( n = 55)...
2019: Frontiers in Psychiatry
Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iyo
High-dose antipsychotic(s) can induce dopamine supersensitivity psychosis in schizophrenia patients. The precise relationship between a drug's blood concentration and the occurrence of dopamine supersensitivity psychosis has not been established. We divided 36 patients with schizophrenia who had undergone treatment mainly with risperidone into two groups: one with normal metabolizing activity of CYP2D6 (n = 15), and the other with lower activity of its variant, CYP2D6*10 (n = 21). The patients' blood concentrations of risperidone and 9-OH-risperidone were measured, and we compared the occurrence of dopamine supersensitivity psychosis episodes between the groups...
March 7, 2019: International Clinical Psychopharmacology
Joelle Wehbé, Chadia Haddad, Sahar Obeid, Souheil Hallit, Georges Haddad
The objectives were to examine the prevalence of obsessive-compulsive disorder (OCD) in hospitalized patients with schizophrenia and to compare the clinical, cognitive, and functional characteristics of schizophrenia patients with and without OCD. This cross-sectional study, performed between May and August 2018, enrolled 308 patients (200 men and 108 women). The prevalence of OCD in patients with schizophrenia was 3.2%. An increase in patients having a mild β was significantly associated with higher social relationship score (β = 1...
March 6, 2019: Journal of Nervous and Mental Disease
Myeongju Cho, Tae Young Lee, Yoo Bin Kwak, Youngwoo Brian Yoon, Minah Kim, Jun Soo Kwon
OBJECTIVE: Recent evidence suggests that adjuvant anti-inflammatory agents could improve the symptoms of patients with schizophrenia. However, the effects of the adjuvant anti-inflammatory agents on cognitive function, general functioning and side effects have not yet been systematically investigated. The present meta-analysis aimed to explore the effects of anti-inflammatory agents in patients with schizophrenia comprehensively. METHOD: We performed a literature search in online databases, including PubMed, EMBASE and the Cochrane Database of Systematic Reviews...
March 13, 2019: Australian and New Zealand Journal of Psychiatry
Paola Bozzatello, Silvio Bellino, Paola Rocca
Background: Clinical and functional outcome improvement in psychotic disorders is a challenge for the investigators. Recent advances offered opportunities for ameliorating the course of the illness during its early stages and for identifying treatment-resistant patients. Patients who had not response to two different antipsychotics, administered at correct doses for a sufficient period, can be operationally considered treatment-resistant. Available evidence suggested that the response's trajectory to the antipsychotic treatment revealed that a small proportion of subjects are poor responders (8...
2019: Frontiers in Psychiatry
Carlos Mugruza-Vassallo, Douglas Potter
Typically, in an oddball paradigm with two experimental conditions, the longer the time between novels the greater P3a amplitude. Here the research question is: Does an oddball paradigm maintain the greater P3a amplitude under several experimental conditions? An EEG study was carried out with an oddball number parity decision task having four conditions in control and schizophrenic participants. Contrary to previous findings (Gonsalvez and Polich, 2002; Polich, 2007) in control participants, non-correlation was found between the time of a novel (N) stimulus condition to the next novel condition and P3a amplitude...
2019: Frontiers in Human Neuroscience
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, Ludger Hargarter
Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18-70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled...
2019: Neuropsychiatric Disease and Treatment
Xiaodan Zhu, Xuebing Xu, Chao Xu, Jingyi Zhang, Xiaofeng Zhang, Li Ma, Juan Liu, Kefang Wang
Purpose: Previous studies have not determined the interactive effects of stress and coping style on cognitive function in patients with schizophrenia, and the current studies have been restricted to the relationship between stress and stress response, which may be associated with cognitive impairment in individuals with schizophrenia. The present research was aimed to determine whether stress is related to cognitive function in patients with schizophrenia. In addition, this research further investigates the moderating effects of coping style on the relationship between stress and cognitive function in patients with schizophrenia on the basis of stress and coping theory...
2019: Neuropsychiatric Disease and Treatment
Kate Haining, Claire Matrunola, Lucy Mitchell, Ruchika Gajwani, Joachim Gross, Andrew I Gumley, Stephen M Lawrie, Matthias Schwannauer, Frauke Schultze-Lutter, Peter J Uhlhaas
BACKGROUND: The current study examined the pattern of neurocognitive impairments in a community-recruited sample of clinical high-risk (CHR) participants and established relationships with psychosocial functioning. METHODS: CHR-participants (n = 108), participants who did not fulfil CHR-criteria (CHR-negatives) (n = 42) as well as a group of healthy controls (HCs) (n = 55) were recruited. CHR-status was assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) and the Schizophrenia Proneness Instrument, Adult Version (SPI-A)...
March 13, 2019: Psychological Medicine
Jean-Pierre Lindenmayer, Stephen R Marder, Carlos Singer, Cynthia Comella, Khody Farahmand, Joshua Burke, Roland Jimenez, Scott Siegert
BACKGROUND: Patients treated with antipsychotics, regardless of psychiatric diagnosis, are at risk for developing tardive dyskinesia (TD), a potentially debilitating drug-induced movement disorder. Valbenazine (INGREZZA; VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat TD in adults. Data from KINECT 4 (NCT02405091) were analyzed to evaluate the long-term effects of VBZ in adults with schizophrenia/schizoaffective disorder (SZD) or mood disorder (MD) and moderate or severe TD...
February 2019: CNS Spectrums
Peter J Weiden, Amy Claxton, Yangchun Du, John Lauriello
BACKGROUND: One of the challenges in schizophrenia long-term trials is that clinical outcomes are often confounded by covert nonadherence to prescribed oral antipsychotics. This is a post hoc analysis (>2 years) of the symptoms and illness trajectory of patients treated with the long-acting injectable (LAI) antipsychotic aripiprazole lauroxil (AL). As adherence to LAIs can be monitored, these data could assess outcome trajectories unaffected by medication discontinuations that may occur with oral antipsychotics...
February 2019: CNS Spectrums
Oscar Patterson-Lomba, Rajeev Ayyagari, Benjamin Carroll
BACKGROUND: Tardive dyskinesia (TD) is typically caused by exposure to antipsychotics, is often irreversible, and can be debilitating. TD symptoms can increase the social stigma of patients with comorbid psychiatric disorders, negatively impact quality of life, and potentially increase medical morbidity and mortality. An increased risk of developing TD has been associated with factors such as older age, female sex, underlying mental illness, and long-term use and higher doses of antipsychotics...
February 2019: CNS Spectrums
Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, María Fernández-Rodríguez, Javier Vázquez-Bourgon, Paula Suárez-Pinilla, Oriol Porta-Olivares
RationaleLong-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. However, there is still a lack of real-world studies assessing the effectiveness of these therapies. OBJECTIVE: This study aimed to explore the safety, tolerability, and treatment response of aripiprazole monohydrate (AOM) once monthly in non-acute but symptomatic adult patients switched from previous therapy with frequently used oral or injectable atypical antipsychotics...
February 2019: CNS Spectrums
Stephen R Marder, Martha Sajatovic, Dan Michel, Joshua Burke, Khody Farahmand, Scott Siegert
OBJECTIVE: To evaluate the long-term safety and tolerability of once-dailyvalbenazine in adults with tardive dyskinesia(TD). METHODS: Data were pooled from KINECT 3 (NCT02274558: 6-week double-blind placebo-controlled period, followed by a 42-week double-blind extension and 4-week drug-free washout) and KINECT 4 (NCT02405091: 48-week open-label treatment period and 4-week drug-free washout). KINECT 3/4 study completers could enroll in a subsequent rollover study (NCT02736955: up to 72weeks of open-label treatment or until valbenazine became commercial available); data from this study were described separately for this analysis...
February 2019: CNS Spectrums
Kimberly Vanover, Steven Glass, Susan Kozauer, Jelena Saillard, Juan Sanchez, Michal Weingart, Sharon Mates, Andrew Satlin, Robert Davis
BACKGROUND: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems. Lumateperone is a potent 5-HT2A antagonist, a mesolimbic/mesocortical dopamine phosphoprotein modulator (DPPM) with pre-synaptic partial agonist and post-synaptic antagonist activity at D2, a glutamate GluN2B receptor phosphoprotein modulator with D1-dependent enhancement of both NMDA and AMPA currents via the mTOR protein pathway and an inhibitor of serotonin reuptake...
February 2019: CNS Spectrums
Steven G Potkin, Jelena Kunovac, Bernard L Silverman, Adam Simmons, Ying Jiang, Lauren DiPetrillo, David McDonnell
BACKGROUND: ALKS 3831, currently under development for the treatment of schizophrenia, is composed of olanzapine (OLZ) and a fixed dose of 10mg of samidorphan. In a Phase 2 study in stable patients with schizophrenia, ALKS 3831mitigated OLZ-associated weight gain while maintaining an antipsychotic efficacy profile similar to OLZ.Study objectiveTo assess the efficacy and safety of ALKS 3831 in patients with acute exacerbation of schizophrenia. METHODS: This was a Phase 3, 4-week, randomized, double-blind, active and placebo (PBO)-controlled study of ALKS 3831 in patients with acute exacerbation of schizophrenia (ClinicalTrials...
February 2019: CNS Spectrums
Eric D Achtyes, Adam Simmons, Anna Skabeev, Ying Jiang, Patricia Marcy, Nikki Levy, Peter J Weiden
Study objectivePatient-reported outcomes and preferences rely on reports of the status of a patient's health condition that comes directly from the patient, without interpretation or qualification by clinicians or investigators. Patient-reported outcomes and preferences have become an accepted approach in drug development. As part of this effort, we assessed the relative importance to patients with schizophrenia of trying a new antipsychotic that might improve symptoms in the context of common antipsychotic side effects, especially weight gain...
February 2019: CNS Spectrums
Catherine Weiss, Peter Zhang, Ross A Baker, Mary Hobart, Nanco Hefting, Stine R Meehan
BACKGROUND: Effective treatments for patients with high levels of negative symptoms of schizophrenia are lacking. Brexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all with subnanomolar potency. Long-term treatment with brexpiprazole demonstrated broad efficacy across all five Marder factor groupings, including positive, negative, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression...
February 2019: CNS Spectrums
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"